(Q38179658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Malignancies: pre and post transplantation strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Bryce Kiberd

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

13 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

published in

Transplantation Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

76-83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439783%20AND%20SRC:MED&resulttype=core&format=json

Spectrum of cancer risk among US solid organ transplant recipients

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer Incidence Among Canadian Kidney Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15 183 Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer risk following organ transplantation: a nationwide cohort study in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer incidence in a kidney-transplanted population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Malignancies after renal transplantation in Taiwan: a nationwide population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer after kidney transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Epidemiologic critique of literature on post-transplant neoplasms in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

The pattern of excess cancer in dialysis and transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

AASLD practice guidelines: Evaluation of the patient for liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Association of CKD and cancer risk in older people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Reduction in cardiovascular death after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Malignancies after kidney transplantation: Hong Kong renal registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer mortality in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Post-transplant de novo malignancies in renal transplant recipients: the past and present

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Long-term cancer risk of immunosuppressive regimens after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Recommendations on screening for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Recommendations on screening for breast cancer in average-risk women aged 40-74 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Reduced lung-cancer mortality with low-dose computed tomographic screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Imaging of cancer predisposition syndromes in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Screening for head and neck cancer in liver transplant candidates: a review of 11 years of experience at the University of Pittsburgh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Guidelines for the referral and management of patients eligible for solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Donor-transmitted malignancies in organ transplantation: assessment of clinical risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Transplant tumor registry: donor related malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

The United Network for Organ Sharing position on using donors with primary central nervous system malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Transplantation risks and the real world: what does 'high risk' really mean?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Informing candidates for solid-organ transplantation about donor risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Screening for Prostate, Breast and Colorectal Cancer in Renal Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

KDIGO clinical practice guideline for the care of kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cost-effectiveness of colorectal cancer screening in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Managing cancer risk and decision making after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer screening in renal transplant recipients: what is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Management of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Non-melanoma skin cancer risk in the Queensland renal transplant population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Characteristics of early and late PTLD development in pediatric solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Epstein-Barr virus infection and posttransplant lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Lymphomas after solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Renal cell carcinoma in transplant recipients with acquired cystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Cancer incidence before and after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Renal tumors in solid organ recipients: clinical and pathologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Screening for renal cancer in recipients of kidney transplants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

mTOR pathway and mTOR inhibitors as agents for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.12.002